Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum)

Acta Tropica

Volumn 118, Issue 2, 2011, Pages 142-151

  Zhang, Weidong ^a   Ahmad, Gul ^a   Torben, Workineh ^a   Siddiqui, Afzal A ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Calpain; Prime boost; Schistosoma; Sm p80; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYTOKINE; DNA VACCINE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MESSENGER RNA; PARASITE ANTIBODY; PARASITE ANTIGEN; PLASMID VECTOR; SCHISTOSOMA VACCINE; SM P80 PROTEIN; UNCLASSIFIED DRUG;

DETECTION METHOD; DISEASE CONTROL; IMMUNE RESPONSE; IMMUNIZATION; PARASITIC DISEASE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PARASITE CONTROL; PARASITE LOAD; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; VACCINATION; VACCINE PRODUCTION; WORM EGG;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CYTOKINES; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED C57BL; PLASMIDS; SCHISTOSOMA MANSONI; TH1 CELLS; TH17 CELLS; TH2 CELLS; VACCINATION; VACCINES, DNA;

SCHISTOSOMA; SCHISTOSOMA MANSONI;

EID: 79955480794     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.01.010     Document Type: Article

References (55)

1. Ahmad G., Torben W., Zhang W., Wyatt M., Siddiqui A.A. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol. 2009, 31:156-161.
2. Ahmad G., Zhang W., Torben W., Damian R.T., Wolf R.F., White G.L., Chavez-Suarez M., Kennedy R.C., Siddiqui A.A. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009, 27:2830-2837.
3. Ahmad G., Zhang W., Torben W., Haskins C., Diggs S., Noor Z., Le L., Siddiqui A.A. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol. Res. 2009, 105:1767-1777.
4. Ahmad G., Zhang W., Torben W., Noor Z., Siddiqui A.A. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int. J. Infect. Dis. 2010, 14:e781-e787.
5. Angeli V., Faveeuw C., Delerive P., Fontaine J., Barriera Y., Franchimont N., Staels B., Capron M., Trottein F. Schistosoma mansoni induces the synthesis of IL-6 in pulmonary microvascular endothelial cells: role of IL-6 in the control of lung eosinophilia during infection. Eur. J. Immunol. 2001, 31:2751-2761.
6. Bergquist N.R., Leonardo L.R., Mitchell G.F. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol. 2005, 21:112-117.
7. Berriman M., Haas B.J., LoVerde P.T., Wilson R.A., Dillon G.P., Cerqueira G.C., Mashiyama S.T., Al-Lazikani B., Andrade L.F., Ashton P.D., Aslett M.A., Bartholomeu D.C., Blandin G., Caffrey C.R., Coghlan A., Coulson R., Day T.A., Delcher A., DeMarco R., Djikeng A., Eyre T., Gamble J.A., Ghedin E., Gu Y., Hertz-Fowler C., Hirai H., Hirai Y., Houston R., Ivens A., Johnston D.A., Lacerda D., Macedo C.D., McVeigh P., Ning Z., Oliveira G., Overington J.P., Parkhill J., Pertea M., Pierce R.J., Protasio A.V., Quail M.A., Rajandream M.A., Rogers J., Sajid M., Salzberg S.L., Stanke M., Tivey A.R., White O., Williams D.L., Wortman J., Wu W., Zamanian M., Zerlotini A., Fraser-Liggett C.M., Barrell B.G., El-Sayed N.M. The genome of the blood fluke Schistosoma mansoni. Nature 2009, 460:352-358.
8. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
9. Bettelli E., Oukka M., Kuchroo V.K. TH-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345-350.
10. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., Ambrozak D.R., Precopio M.L., Scheinber P., Alder N.C., Roderer M., Koup R.A., Douek D.C., Hill A.V., McShane H. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 2007, 37:3089-3100.
11. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997, 15:749-795.
12. Brombacher F., Kastelein R.A., Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003, 207-212.
13. Coon D.R. Schistosomiasis: overview of the history, biology, clinicopathology, and laboratory diagnosis. Clin. Microbiol. Newslett. 2005, 27:163-169.
14. Diehl S., Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 2002, 39:531-536.
15. El Ridi R., Mahrous A., Afifi A., Montash M., Velvek J., Jezek J. Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to Schistosomiais. Scand. J. Immunol. 2001, 54:477-485.
16. El Ridi R., Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009, 27:666-673.
17. El Ridi R., Tallima H., Mahana N., Dalton J.P. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory-secretory candidate vaccine antigens. Microbes Infect. 2010, 12:700-709.
18. Elyaman W., Bradshaw E.M., Uyttenhove C., Dardalhon V., Awasthi A., Imitola J., Bettelli E., Oukka M., van Snick J., Renauld J.C., Kuchroo V.K., Khoury S.J. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12885-12890.
19. Fenwick A. Waterborne infectious diseases - could they be consigned to history?. Science 2006, 313:1077-1081.
20. Fenwick A., Webster J.P., Bosque-Oliva E., Blair L., Fleming F.M., Zhang Y., Garba A., Stothard J.R., Gabrielli A.F., Clements A.C., Kabatereine N.B., Toure S., Dembele R., Nyandindi U., Mwansa J., Koukounari A. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 2009, 136:1719-1730.
21. Fallon P.G., Smith P., Richardson E.J., Jones F.J., Faulkner H.C., Snick J.V., Renauld J.C., Grencis R.K., Dunne D.W. Expression of Interleukin-9 leads to Th2 cytokine dominated responses and fatal enteropathy in mice with chronic Schistosoma mansoni infections. Intect. Immun. 2000, 68:6005-6011.
22. Gazinelli R.T., Oswald I.P., James S.L., Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J. Immunol. 1992, 148:1792-1796.
23. Gazinelli R.T., Wysocka M., Hayashi S., Denkers E.Y., Hieny S., Caspar P., Trinchieri G., Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 1994, 153:2533-2543.
24. Gilbert S., Moorthy V., Andrews L., Pathan A., McConkey J., Vuola J., Keating S., Berthoud T., Webster H., McShane H., Hill A. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24:4554-4561.
25. Glück J., Rogala B., Rogala E., Oles E. Allergen immunotherapy in intermittent allergic rhinitis reduces the intracellular expression of IL-4 by CD8+ T cells. Vaccine 2007, 26:77-81.
26. Gougerot-Podicala M.A., Elbium C., Chollet-Martin S. Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines. Pathol. Biol. (Paris) 1996, 44:36-41.
27. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., Burnet S., Cellerai C., Erlwein O., Barber T., Moog C., Liljestrom P., Wagner R., Wolf H., Kraehenbuhl J.P., Esteban M., Heeney J., Frachette M.J., Tartaglia J., McCornack S., Babiker A., Weber J., Pantaleo G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008, 205:63-77.
28. Hotez P.J., Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl. Trop. Dis. 2009, 3:e485.
29. Hotez P.J., Molyneux D.H., Fenwick A., Kumaresan J., Sachs S.E., Sachs J.D., Savioli L. Control of neglected tropical diseases. N. Engl. J. Med. 2007, 357:1018-1027.
30. James C.E., Hudson A.L., Davey M.W. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol. 2009, 25:538-539.
31. Jankovic D., Aslund L., Oswald I.P., Caspar P., Champion C., Pearce E., Coligan J.E., Strand M., Sher A., James S.L. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J. Immunol. 1996, 157:806-814.
32. Jankovic D., Wynn T.A., Kullberg M.C., Hieny S., Caspar P., James S., Cheever A.W., Sher A. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms. J. Immunol. 1999, 162:345-351.
33. Jia Y., Li H., Chen W., Li M., Lv M., Feng P., Hu H., Zhang L. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther. 2006, 13:1351-1359.
34. Kolibab K., Yang A., Derrick S.C., Waldmann T.A., Perera L.P., Morris S.L. Highly persistent and effective prime/boost regimens against tuberculosis using a multi-valent MVA based tuberculosis vaccine molecularly adjuvanted with IL-15. Clin. Vaccine Immunol. 2010, 17:793-801.
35. Koopman G., Mortier D., Hofman S., Mathy N., Koutsoukos M., Ertl P., Overend P., van Wely C., Thomsen L.L., Wahren B., Voss G., Heeney J.L. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol. 2008, 89:540-553.
36. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 2009, 21:23-29.
37. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21:346-351.
38. McShane H., Pathan A., Sander C., Keating S., Gibert S., Huygen K., Fletcher H., Hill A. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 2004, 10:1240-1244.
39. Mitchell G.B., Betty A.N., Caswell J.L. Effects of interleukin-8 and granulocyte colony-stimulating factor on priming and activation of bovine neutrophils. Infect. Immun. 2003, 71:1643-1649.
40. Ohta N., Kumagai T., Maruyama H., Yoshida A., He Y., Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol. Int. 2004, 53:175-181.
41. Osada Y., Kumagai T., Hato M., Suzuki T., El-Malky M., Asahi H., Kanazawa T., Ohta N. Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. Vaccine 2005, 23:2813-2819.
42. Pancre V., Monte D., Delanoye A., Capron A., Auriault C. Interleukin-6 is the main mediator of the interaction between monocytes and platelets in killing of Schistosoma mansoni. Eur. Cytokine Netw. 1990, 1:15-19.
43. Pearce E.J., James S.L. Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo. Parasite Immunol. 1986, September:513-527.
44. Reali E., Spisani S., Gavioli R., Lanza F., Moretti S., Traniello S. IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils. Immunol. Cell Biol. 1995, 73:234-238.
45. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., Lloyd J.D., Paz M., Villalovos R.M., Pompa J. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect. Immun. 2003, 71:3844-3851.
46. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., Lloyd J.D., Pompa J., Villalovos R.M., Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003, 21:2882-2889.
47. Siddiqui A.A., Pinkston J.R., Quinlin M.L., Kavikondala V., Rewers-Felkins K.A., Phillips T., Pompa J. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005, 12:3-8.
48. Siddiqui A.A., Pinkston J.R., Quinlin M.L., Saeed Q., White G.L., Shearer M.H., Kennedy R.C. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005, 23:1451-1456.
49. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 2006, 6:411-425.
50. Stockinger B., Veldhoen M., Martin B. Th17 T cells: linking innate and adaptive immunity. Sem. Immunol. 2007, 19:353-361.
51. Tallima H., Salah M., Guirguis F.R., El R.R. Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. Cytokine 2009, 48:239-245.
52. Tan S.Y., Ahana A. Theodor Bilharz (1825-1862): discoverer of schistosomiasis 5. Singapore Med. J. 2007, 48:184-185.
53. Webster J.P., Koukounari A., Lamberton P.H., Stothard J.R., Fenwick A. Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. Parasitology 2009, 136:1789-1799.
54. Zhang W., Ahmad G., Torben W., Noor Z., Le L., Damian R.T., Wolf R.F., White G.L., Chavez-Suarez M., Podesta R.B., Kennedy R.C., Siddiqui A.A. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J. Infect. Dis. 2010, 201:1105-1112.
55. Zhang W., Ahmad G., Torben W., Siddiqui A.A. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol. 2010, 32:252-258.